Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases - Wikidata - wikimedia - TriplyDB

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

http://www.wikidata.org/entity/Q33620317

about

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications Prospects of immune checkpoint modulators in the treatment of glioblastoma BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.Recent advances and future of immunotherapy for glioblastoma.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.Special topics in immunotherapy and radiation therapy: reirradiation and palliation Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.Embracing rejection: Immunologic trends in brain metastasis.The Microenvironmental Landscape of Brain Tumors.Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).Immune Checkpoint Inhibitors for Brain Metastases.Challenges in the delivery of therapies to melanoma brain metastases.Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.What have we learned from cancer immunotherapy in the last 3 years?Exudative Polymorphous Vitelliform Retinopathy: Importance of Early Recognition of the Condition in Patients with Metastatic Melanoma.Immune checkpoint inhibition in patients with brain metastases.Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.Innate and acquired immune surveillance in the postdissemination phase of metastasis.Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease

P2860

Q26775546-302F0594-1028-4AC6-AA71-AC1405E423F1 Q28081371-B532F215-3D7B-41D0-B565-44D6A9F42325 Q34667825-1F4B76AB-9740-4746-987C-D8D7DF10A0EC Q35798996-578C924C-1ECD-48DD-A2CC-6F4EB700AA72 Q35815273-BFE5BC24-7083-4FA9-8350-B519EC8AD157 Q35820476-892FEF3C-5FFC-45FC-A34C-68DDCE9B00E2 Q36028546-BCB59B05-E2B5-409F-8974-BD7EB82FF997 Q36082506-9D74383B-8472-4342-B0B1-999EC2D8EF62 Q37239071-DDBCC785-BE68-44F2-BD70-1A832D5F254D Q37584395-52CC61C2-3197-49C8-899F-62AB1FEBF177 Q37606693-5E3F9BA8-B2C8-444C-8664-19E9661982C8 Q37741143-9B3E6758-CDC9-482B-B585-4F8D14F2D2F2 Q38771929-2E1B1F69-AC5E-4A2F-931A-BBB58B82CBDB Q38775281-A4B3FF46-EDC9-41D9-83A1-0A2C53C4B5F0 Q38953017-2A1EE245-7182-4EF5-84A3-1D3B5C3B1D92 Q39178065-6EFBCC09-DC9A-44A9-A3B5-16313915FFF4 Q39229266-408BC912-15F8-49EB-8AD4-A1F98D756A7C Q39247421-3AF2CA48-EEB8-476D-BCBC-04103DAD799A Q39331752-CFC77B0A-AF9D-4BF7-A2D3-1F5BE0D4E0E6 Q39688544-C4E5BA51-8927-4CB2-9480-3A207400C2A2 Q40065733-E38502C1-6972-4B5C-8737-C7752630A4CF Q42049392-D65F2AE0-20AB-4F14-B4C0-2BE9E2A43A03 Q42370384-73AB1CC7-27A1-46BE-86A0-CB4511318577 Q46675575-2A68D36B-5C15-4BF0-8F7B-CFCC6E3FAA3A Q47825909-EF344579-8C11-4FDB-A29C-9F420E7FCCC0 Q50048813-DA5DB0C0-4702-44CF-AA9E-DE037127C685 Q50651030-EAF60B5A-63F6-439D-9AA5-F1DD5316021D Q55283310-B1FC52BE-8C77-4456-8715-1F913200DDCB Q57490955-607BF90D-C54D-4433-AFF2-4B19227138B8

P2860

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

http://www.wikidata.org/entity/Q33620317

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

@ast

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

@en

type

label

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

@ast

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

@en

prefLabel

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

@ast

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

@en

P1433

Q33620317-A8DF20CF-2066-4318-B12B-1846F0223464

P1476

Q33620317-4AB94260-B456-4B8E-B119-9933EFA32C21

P2093

Q33620317-09B98349-CCF3-418E-BFDE-B54AF5E85909

Q33620317-109671AD-756E-4AAE-BF3D-D01B3BB1BF26

Q33620317-112868CD-3552-4A0E-80B3-C773B90B0282

Q33620317-20B3DB5E-7B8F-4030-8023-B4E8AC8252A3

Q33620317-52153240-6C3B-43B5-89EC-466754819947

Q33620317-9D4D5914-6DD2-47E2-8F44-20CC3BC8724B

Q33620317-B1F83BE5-BEB1-4647-BC38-85F4078DBC80

Q33620317-BFE0FEB8-F858-44C6-A543-3617690F6A72

P2860

Q33620317-04FF79A3-9910-41CE-B579-3CAAB04D10D1

Q33620317-16795C21-7720-455E-AC99-B0558FD45C39

Q33620317-1CD40865-DBBC-498C-B115-6BE742173F65

Q33620317-20460793-CA85-4C68-9887-FE115082D698

Q33620317-231AF5CB-B008-4590-8003-46203E3A588E

Q33620317-247034E0-9A62-4048-94A0-1C33A2E54BB6

Q33620317-30A30B6F-DCE0-4331-8123-CEB5CC6E317F

Q33620317-3D5132F9-F143-4ABD-83E0-211B79750B9B

Q33620317-4542B4E0-26A7-4036-B03E-64A9A098BC01

Q33620317-57C8012F-BB2A-4C3D-8169-5AC9DAA493E4

P2888

Q33620317-0261871D-0D87-42E7-900C-F2954C47E2D8

P304

Q33620317-AD6D4CE8-8F87-4C5F-98A0-96FDD54DFE50

P31

Q33620317-4B846E35-55A2-4EC0-8F34-56191D3F1C32

P356

Q33620317-CB4270E4-C0EC-4F68-BAB5-09EFAE35729E

P433

Q33620317-5B144181-2A7F-4E4D-A4DE-28B9D95073EA

P478

Q33620317-49D56CB3-307E-40C1-9979-15FC6D693FE1

P50

Q33620317-1B907EE0-4415-438A-8B4D-20623866457B

Q33620317-2E33814C-8141-4610-83AF-CF7A1A3583D9

Q33620317-3B043D8C-1497-4534-AFD5-A80AC369203C

Q33620317-3BF8D242-4F55-44F1-B96C-9B04A9B30448

Q33620317-517A90DC-6C57-47E1-A455-2909BD7B7835

Q33620317-60D3355A-8037-43B4-921D-CA6076F84D42

Q33620317-96120F2E-79DB-49AD-A617-12BCAF9D45DB

Q33620317-D274EC6C-17F6-40F7-9C19-AE56EE92BD26

Q33620317-D2D5141A-B687-41A5-820D-0392D34B78FA

Q33620317-E584C3C7-D28E-4034-9249-40A872A8E455

P577

Q33620317-1847E125-F9CB-499E-AC3E-C84332256E28

P5875

Q33620317-03096904-A583-464B-BFDF-6CEF20678046

P6179

Q33620317-D6073733-B582-4294-9395-BDE10D5F28CD

P698

Q33620317-F81A9F4F-4340-42CB-933A-A5D1EFBBC9CE

P921

Q33620317-FF5E94D3-45C1-459F-8979-BAF6CF3B1D1C

P932

Q33620317-281B6D4D-CBE6-4990-B5EC-7E62C821CE32

P356

S11060-014-1400-Y

P1433

Journal of Neuro-Oncology

P1476

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

@en

P2093

Alessandro Scoppola

http://www.w3.org/2001/XMLSchema#string

Andrea Antonuzzo

http://www.w3.org/2001/XMLSchema#string

Anna Maria Di Giacomo

http://www.w3.org/2001/XMLSchema#string

Ester Simeone

http://www.w3.org/2001/XMLSchema#string

Francesco Cognetti

http://www.w3.org/2001/XMLSchema#string

Laura Ridolfi

http://www.w3.org/2001/XMLSchema#string

Michele Guida

http://www.w3.org/2001/XMLSchema#string

Paolo Antonio Ascierto

http://www.w3.org/2001/XMLSchema#string

P2860

Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Determinants of survival in patients with brain metastases from cutaneous melanoma.

Trafficking of immune cells in the central nervous system

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

P2888

s11060-014-1400-y

P304

109-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-014-1400-Y

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Michele Del Vecchio

Massimo Guidoboni

Paolo Marchetti

Virginia Ferraresi

Lorenza Di Guardo

Francesco Spagnolo

V Chiarion-Sileni

P577

2014-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260212601

http://www.w3.org/2001/XMLSchema#string

P6179

1048201517

http://www.w3.org/2001/XMLSchema#string

P698

24532241

http://www.w3.org/2001/XMLSchema#string

P921

P932

4023079

http://www.w3.org/2001/XMLSchema#string